TD2021CG/LH

Summary of Major Modifications

The Technical Document on Analysis, Reporting and Management of Urinary human Chorionic Gonadotrophin (hCG) and Luteinizing Hormone (LH) Findings in Male Athletes, TD2021CG/LH, has been aligned with the 2021 World Anti-Doping Code (Code) and the recently approved 2021 International Standard for Laboratories (ISL) ; and, the other International Standards, which are set to come into force on 1 January 2021.

The main changes in the TD2021CG/LH include:

Article 3.0 Analytical Testing Strategy

- The possible use of total hCG assays for the Initial Testing Procedure (ITP) has been reintroduced to facilitate the analytical strategy. A comment has also been reintroduced explaining the association of “familial hCG” with elevated concentrations of total hCG in serum and urine;

- Further clarifications are given regarding the selection of hCG assays for the ITP and Confirmation Procedures (CP), as well as the management of reported hCG results.

Article 3.1.2 Confirmation Procedure (CP)

- The Siemens EXL Dimension assay has been included as an example of Fit-for-Purpose immunoassays for quantification of hCG α/β heterodimer in urine.

Article 4.0 Interpretation and Reporting of Results

- It has been specified that Decision Limits (DL) and adjusted DLs (if SG > 1.018) for hCG, as well as measured hCG and LH concentrations shall be expressed truncated to three (3) significant figures.

In addition:

- Formatting as well as updating of terms and definitions, where relevant;
- Footnotes have been inserted as Comments where relevant in the main text.

The TD2021CG/LH replaces the former TD2019CG/LH and becomes effective on 1 April 2021.